Global Biologics Market Trends and Growth Propellers 2024

The global market for biologics features a fragmented competitive landscape with stakeholders being some of the world’s most influential pharmaceutical companies and several domestic companies, which are vying for a share in the highly profitable market, observes Transparency Market Research (TMR) in a recent report. “A popular trend in the market is strategic mergers and acquisitions, with big companies wanting to expand their services and manufacturing units globally and enhancing product portfolios by co-development activities and licensing deals,” states a TMR analyst.

Pharmaceutical giants such as Eli Lilly and Co., Bristol-Myers Squibb, Novartis, AstraZenca, and GlaxoSmithKline Plc. have invested billions of dollars in the field of biologics, which have translated into capacity expansion and focused research and development. With an aim of gaining a quick hold on the vast growth opportunities, established players are entering into strategic collaborations and investing in local manufacturers in emerging economies for product developments and manufacturing activities.

View Report @ http://www.transparencymarketresearch.com/global-biologics-market.html

Point in case is the investment of US$500 mn by Novartis for building cell-culture based manufacturing facility in Asia in collaboration with its Asia Pacific HQ in Singapore. In the near future, the global market for biologics is expected to witness considerable traction and tread along a healthy growth path.

Monoclonal Antibodies to Emerge as Leading Product Segment
Transparency Market Research states that the global biologics market will expand at a healthy 10.9% CAGR from 2016 to 2024. If the number holds true, the market, which is expected to value at US$209, 779 mn in 2016, is expected to rise to US$479, 752 mn by 2024. In terms of product variety, the segment of monoclonal antibodies is expected to dominate the market, with an annual share of 43% in 2016 and a CAGR of 11.9% from 2016 through 2024. Geographically, the global biologics market will be led by North America, which is expected to account for a 44.89% share in the global market in 2016 and expand at a 9.6% CAGR from 2016 through 2024.

Promise of Profitable Returns to Drive More Investments in Market

The vast funds directed by pharmaceutical companies towards research and development activities, manufacturing, and the process of trial and approval of new product varieties often reflect on the high costs of products upon approval. It has been observed that drug companies charge premium prices for innovative biologics, with profit margins as high as 20-40%. Biologics have been noted to provide effective treatment for many complex diseases, which have mostly lacked notable treatment options so far. As a result, despite the high prices, demand for biologics usually witnesses an upward trend.

According to a pharmacy management service provider Express Scripts, only about 2% of people in the U.S. used biologic drugs. Regardless of this, biologics account for as much as 40% of prescription drug spending in the country. In general, biologics treatment costs about 22 times more in comparison to small molecule drugs. Owing to such profitable returns, the market has witnessed a vast influx of investment from notable pharmaceutical companies in the past few years. The trend is expected to remain strong in the next few years as well, making highly profitable returns one of the key factors bringing in more investments and driving the overall development of the market.

High Initial Capital Requirement and Complex Regulatory Approval Process to Hinder Market Growth

Biologics have demonstrated a relatively higher success rate of approval compared to traditional drugs. However, the total time required for clinical trials and approvals is much longer owing to stringent manufacturing processes, regulatory pathways, and a variety of product parameters. This leads to a significant increase in the cost of capital required for R&D and marketing of biologics as compared to traditional drugs. The scenario has deterred many small vendors from venturing into the global biologics market and is considered a key restraint for the market’s overall development.

This review of the market is based on a recent report published by TMR, titled “Biologics Market (Product - Monoclonal Antibodies, Vaccines, Cell Therapy, Recombinant Hormones/Proteins, and Gene Therapy; Applications - Infectious Diseases, Oncology, Immunology, and Autoimmune Diseases) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024.”

Get accurate market forecast and analysis on the Biologics Market. Request a sample to stay abreast on the key trends impacting this market.

http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=15509

For the study, the market has been segmented as follows:

Global Biologics Market – By Product

Monoclonal Antibodies
Vaccines
Recombinant Hormones/Proteins
Cell Therapy
Gene Therapy
Others
Global Biologics Market – By Applications

Oncology
Infectious Diseases
Immunology
Autoimmune Diseases
Others
Global Biologics Market – By Region

North America
U.S.
Canada
Latin America
Brazil
Argentina
Rest of Latin America
Europe
Germany
UK
Italy
Spain
France
Rest of Europe
Asia Pacific (APAC)
China
India
Japan
Australia
New Zealand
Rest of Asia Pacific
Middle East and Africa (MEA)
Saudi Arabia
UAE
RSA
Rest of MEA

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.